

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2015

DESPATCHED ON 24TH MARCH 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11, A68; B51, B53; Cw15, Cw18; DR4, DR11; DQ7, DQ8

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested	18	18	17	17	16	16	15	16			
Positive	0	0	0	0	7	13	5	3			
Negative	18	18	17	17	9	3	10	13			
NT/Equivocal	3	3	4	4	4	4	5	4			
% Positive	0.0%	0.0%	0.0%	0.0%	43.8%	81.3%	33.3%	18.8%			
% Negative	100.0%	100.0%	100.0%	100.0%	56.3%	18.8%	66.7%	81.3%			
Consensus	Negative	Negative	Negative	Negative	Not Assessed	Positive	Not Assessed	Negative			
HLA Antibody Specificity (Defined By CDC)	DQ1	DQ3	A2, B17	A9, DR15	DQ1	DQ3	A2, B17	A9, DR15			
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	Samples delayed in post
11	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
12	YES	YES	Negative	Negative	Negative	Negative	Weak Positive	Positive	Negative	Negative	
14	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
15	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
20	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
23	YES	YES	Negative	Negative	Equivocal	Negative	Negative	Positive	Equivocal	Negative	
24	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	
25	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
28	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
34	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
35	YES	NO	Negative	Negative	Negative	Negative					
38	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
39	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	Poor cell viability
41	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	
42	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
45	YES	YES	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
51	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
54	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
58	YES	YES	Negative	Negative	Negative	Equivocal	Positive	Positive	Positive	Negative	
62	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2015

DESPATCHED ON 24TH MARCH 2015

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	NT	NT	NT	NT	NT	NT	NT	NT		10	10
11						4			80	80	80
12	5%	5%	5%	5%	15%	50%	5%	10%		99	95
14	0	0	0	0	4	8	4	0		>90	>90
15	1	1	1	1	1	1	1	1		95	95
20	1	1	1	1	4	2	1	1		90	90
23	1	1		1	1	4		1		90	90
24	20%	20%	10%	20%	30%	60%	50%	40%		90	80
25	1	1	1	1	2	4	1	1		99	99
28	1	1	1	1	NT	NT	NT	NT		90	10
34	NT	NT	NT	NT	NT	NT	NT	NT		70	50
35	1	1	1	1					90	60	
38	1	1	1	1	1	4	1	1	95	90	90
39					4	6	4	2	98		98
41	NT	NT	NT	NT	NT	NT	NT	NT			
42	<10%	<10%	<10%	<10%	<10%	<10%	<10%	<10%	90		90
45	1	1	1	1	4	6	1	4		99	90
51	0	0	0	0	0	6-8	0	0		95	95
54	<10%	<10%	<10%	<10%	20%	90%	80%	10%		95	90
58	5%	5%	5%	5-10%	30%	90%	90%	5%		95	95
62	1	1	1	1	1	1	1	1		99	99

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2015

DESPATCHED ON 24TH MARCH 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A11, A68; B51, B53; Cw15, Cw18; DR4, DR11; DQ7, DQ8

			Summary of Results							
			PBL/T-Cells				B-Cells			
Total tested			14	14	14	13	12	12	12	12
Positive			0	0	0	0	1	4	2	0
Negative			14	14	14	13	11	8	10	12
NT/Equivocal			4	4	4	5	5	5	5	5
% Positive			0.0%	0.0%	0.0%	0.0%	8.3%	33.3%	16.7%	0.0%
% Negative			100.0%	100.0%	100.0%	100.0%	91.7%	66.7%	83.3%	100.0%
Consensus			Negative	Negative	Negative	Negative	Negative	Not Assessed	Negative	Negative
HLA Antibody Specificity (Defined By CDC)			DQ1	DQ3	A2, B17	A9, DR15	DQ1	DQ3	A2, B17	A9, DR15
Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT			
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
9	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
11	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
12	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
14	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative
15	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
20	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
24	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
25	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
28	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
34	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
35	YES	NO	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
38	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
39	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
41	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
42	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
45	YES	YES	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative
51	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
58	YES	YES	Negative	Negative	Negative	Equivocal	Positive	Positive	Positive	Negative

Samples delayed in post
Results not reportable

Poor B cell viability
Poor cell viability

Poor cell viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2015

DESPATCHED ON 24TH MARCH 2015

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	NT	NT	NT	NT	NT	NT	NT	NT		10	10
11	NT	NT	NT	NT	NT	NT	NT	NT	80	80	80
12	5%	5%	5%	5%	5%	10%	5%	5%		99	95
14	0	0	0	0	0	6	2	0		>90	>90
15	1	1	1	1	1	1	1	1		95	95
20	1	1	1	1	1	1	1	1		90	90
24	10%	10%	10%	10%	20%	50%	20%	10%		90	80
25	1	1	1	1	1	1	1	1		99	99
28	1	1	1	1	NT	NT	NT	NT		90	10
34	NT	NT	NT	NT	NT	NT	NT	NT		70	50
35	1	1	1	1					90	60	
38	1	1	1	1	1	1	1	1	95	90	90
39									98		98
41	NT	NT	NT	NT	NT	NT	NT	NT			
42	<10%	<10%	<10%	<10%	<10%	<10%	<10%	<10%	90		90
45	1	1	1	1	1	1	4	1		99	90
51	0	0	0	0	0	0	0	0		95	95
58	5%	5%	5%	5-10%	10%	90%	90%	5%		95	95